Your search for major depressive disorder returned 71 results

Dr Amit Akirov examines the evidence suggesting associations between migraine and major depressive disorder (MDD).

Testing for genetic variants may allow clinicians to predict how patients with major depressive disorder metabolize antidepressants.

Authors of a paper share their perspectives on the topic of chronic pain in individuals with mental health disorders.

Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME) is a disorder characterized by marked fatigue, exertion induced malaise, cognitive clouding (or brain fog), impaired academic/work performance, disrupted sleep, and joint/muscle pain.

A diagnosis of amyotrophic lateral sclerosis can be overlooked by clinicians unfamiliar with the various signs of the disease.

Paul G. Mathew, MD and Steven D. Bender, DDS, uniquely encounter patients with TMD and migraine in their respective practice and offer their insight regarding the diagnosis and management this often overlooked comorbidity.

Can mere light become a revolutionary new treatment for traumatic brain injury, posttraumatic stress disorder, depression, stroke, Parkinson disease, and Alzheimer disease?

A narrative review summarizes recent data on the pathophysiology, epidemiology, and burden of disease and treatment of menstrual migraine.

Recent shifts in studies of sex and gender reiterate the critical need to tailor mental health care to each patient and to remain mindful about assumptions regarding sex and gender and their role in a given patient’s specific challenges.

There is an emerging view that sleep disorders are not merely symptoms of psychiatric conditions; instead there may be a complex, bidirectional relationship between psychiatric and sleep disorders.

In this review, study authors discuss and summarize the current evidence for the evaluation and management of the most prevalent and well-described conditions in SCI, including impact of SCI on sleep and daytime function.

Responses to treatment depend on the target chosen, with 5 targets yielding positive outcomes, including the ventral anterior limb of the internal capsule, subthalamic nucleus, nucleus accumbens, ventral capsule/ventral striatum, or inferior thalamic peduncle, all involving fronto-striato-thalamocortical circuits.

Lead author Nagy Mekhail, MD, PhD discusses the importance of neuromodulation, specifically a closed loop spinal cord stimulation system (SCS), for the management of chronic pain.

Atrial fibrillation, which affects up to 46.3 million people globally and 2.7 to 6.1 million individuals in the US, may represent a modifiable risk factor for acute stroke.

Common comorbidities in OSA such as cardiovascular disease and metabolic abnormalities, may confer a higher risk for the development of mental and cognitive impairment in patients with OSA compared with the general population.

The clinical approach to management of Cushing disease is often complex and education on a clear approach is paramount.

This newly established center at Johns Hopkins is reinvigorating research on the potential therapeutic applications of psychedelics.

Rates of HIV-associated dementia have decreased from approximately 50% in the pre-cART era to 2% currently. However, roughly 50% of patients treated with cART have the milder forms of HIV-associated neurocognitive disorder (HAND).

The authors highlight what is known about the development of new daily persistent headache (NDPH), explain how to diagnose and manage patients with NDPH, and discuss possible future therapies.

Research highlights the need for healthcare professionals to proactively and directly address the issues and risks of DMTs in terms of MS patients’ family planning activities.

When combined with other serotonergic agents, selective serotonin reuptake inhibitors can lead to a potentially fatal condition called serotonin syndrome, the incidence of which is likely underestimated.

Research study results showed that treatments for multiple sclerosis precipitated headaches and migraines.

Georgia has been added to the growing list of states, including Kentucky, Ohio, Mississippi, and Tennessee, that have passed so-called fetal heartbeat bills.

Jonathan Miner, MD, PhD, and Karin Nielsen-Saines, MD, MPH, discuss the latest insights about neurologic complications of ZVI and knowledge gaps that still exist in this field.

Clinicians should know that chemotherapy-induced cognitive impairment, chemobrain, chemofog, or whatever you want to call it is a real phenomenon.

Perhaps it is that tension between undeniable differences and inevitable merging that has led to more recent calls for cross-disciplinary cooperation.

Depression is the most frequently observed psychiatric disorder in HD, with an estimated prevalence of 40% to 50%.

Multiple system atrophy is a rare, progressive neurodegenerative condition for which there is currently no cure.

The new guidelines will facilitate the design and development of clinical trials to test new therapies to minimize the burden of neurologic disability produced by neurosarcoidosis.

A rapid increase in the female-to-male ratio of MS incidence has been observed through several population studies.